Montréal company developing hyperspectral retinal imaging and an AI platform that analyses retinal images for eye disease and Alzheimer's risk. Its cameras are FDA-cleared; its AI analysis tests are not.
Canadian innovation builds a brighter tomorrow.
Montréal company developing hyperspectral retinal imaging and an AI platform that analyses retinal images for eye disease and Alzheimer's risk. Its cameras are FDA-cleared; its AI analysis tests are not.
Its FDA 510(k) summary K231230 (November 2023) lists Optina Diagnostics, Inc. at 8200 Decarie Blvd, Montréal, as applicant for the Optina-4C hyperspectral retinal camera. accessdata.fda.gov
Received FDA Breakthrough Device Designation in 2019 for a retinal imaging platform that uses AI to analyse hyperspectral retinal images to aid the diagnosis of Alzheimer's disease. prnewswire.com
Raised a $24 million Series A in October 2021 led by DigitalDx Ventures, with Desjardins Capital, Hike Ventures and others. betakit.com
The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator committed up to US$2.1M to Optina in January 2022 — a ceiling, not an amount stated as paid. newswire.ca
Products Optina Diagnostics publishes on its own site. Each card links to the page it was taken from.
AI eye-care platform
Company describes a retinal imaging and AI platform for age-related macular degeneration that detects early and intermediate retinal disease features with a roughly one-second scan, identifies high-risk patients and monitors progression.
Learn moreHyperspectral retinal camera
FDA-cleared Class II ophthalmic camera intended to capture images of the retina at multiple wavelengths under mydriatic conditions. The clearance covers image capture only, not AI analysis.
SourceAnnounced rounds only, newest first. Undisclosed amounts are shown as undisclosed.
Oct 29, 2021
Investors: DigitalDx Ventures, Desjardins Capital, Hike Ventures, Advisors Fund, MedTeq, Biomed Propulsion
Publicly announced partnerships.
Its Diagnostics Accelerator committed up to US$2.1M in 2022 toward Optina's retinal imaging and AI tests for Alzheimer's disease.
The ADDF's Diagnostics Accelerator committed up to US$2.1M to Optina, whose retinal imaging and AI one-second eye scan is aimed at non-invasive diagnostic tests for Alzheimer's disease.
Optina's Series A was led by DigitalDx Ventures. The company said it was working toward an FDA submission for its awAIr cerebral amyloid status test.
The FDA cleared Optina's MHRC-C1 mydriatic hyperspectral retinal camera, which the company described as a first step toward its AI-based Retinal Deep Phenotyping platform.
Sourced from the company's own pages or announcements.
David Lapointe
Chief Executive Officer (as of January 2022)
Terms the company uses about its own work.
Other companies in Digital Health & HealthTech.
Discover companies, track funding, explore career opportunities and stay informed about Canada’s growing tech ecosystem.